Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 478-486

  Guo, Haitao ^a   Pan, Xiaoben ^a   Mao, Richeng ^a,c   Zhang, Xianchao ^a   Wang, Lijuan ^a   Lu, Xuanyong ^a   Chang, Jinhong ^a   Guo, Ju Tao ^a   Passic, Shendra ^a   Krebs, Fred C ^a   Wigdahl, Brian ^a   Warren, Travis K ^b   Retterer, Cary J ^b   Bavari, Sina ^b   Xu, Xiaodong ^c   Cuconati, Andrea ^c   Block, Timothy M ^a,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHLORIN E6; CHLOROPHYLLIDE; GENE PRODUCT; HEMIN; PORPHINE; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DENGUE VIRUS; DRUG STRUCTURE; ENCEPHALOMYOCARDITIS VIRUS; FLAVIVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; JUNIN VIRUS; MARBURG VIRUS; NONHUMAN; PRIORITY JOURNAL; RNA VIRUS; SCREENING; TACARIBE ARENAVIRUS; VIRION; VIRUS MORPHOLOGY;

ANTIVIRAL AGENTS; ARENAVIRUS; CHLOROPHYLLIDES; DENGUE VIRUS; FILOVIRIDAE; FLAVIVIRUS; HEP G2 CELLS; HEPADNAVIRIDAE; HEPATITIS B VIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; PORPHYRINS;

EID: 78751695583     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00989-10     Document Type: Article

References (32)

1. Bleicher, K. H., H. J. Bohm, K. Muller, and A. I. Alanine. 2003. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2:369-378.
2. Block, T. M., H. Guo, and J. T. Guo. 2007. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 11:685-706, vii.
3. Bremer, C. M., C. Bung, N. Kott, M. Hardt, and D. Glebe. 2009. Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell. Microbiol. 11:249-260.
4. Cheng, G., et al. 2008. A virocidal amphipathic - helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 105:3088-3093.
5. Cheng, Y., et al. 2010. A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro. Antimicrob. Agents Chemother. 54:197-206.
6. DeCamp, D. L., et al. 1992. Specific inhibition of HIV-1 protease by boronated porphyrins. J. Med. Chem. 35:3426-3428.
7. Dryden, K. A., et al. 2006. Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol. Cell 22:843-850.
8. Egner, P. A., A. Munoz, and T. W. Kensler. 2003. Chemoprevention with chlorophyllin in individuals exposed to dietary aflatoxin. Mutat. Res. 523-524:209-216.
9. Egner, P. A., et al. 2001. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl. Acad. Sci. U. S. A. 98:14601-14606.
10. Green, S., and A. Rothman. 2006. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19:429-436.
11. Guo, H., C. E. Aldrich, J. Saputelli, C. Xu, and W. S. Mason. 2006. The insertion domain of the duck hepatitis B virus core protein plays a role in nucleocapsid assembly. Virology 353:443-450.
12. Guo, H., et al. 2007. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J. Virol. 81:12472-12484.
13. Guo, H., R. Mao, T. M. Block, and J. T. Guo. 2010. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J. Virol. 84:387-396.
14. Guo, J. T., T. Zhou, H. Guo, and T. M. Block. 2007. Alpha interferon-induced antiviral response noncytolytically reduces replication defective adenovirus DNA in MDBK cells. Antiviral Res. 76:232-240.
15. Hoofnagle, J. H., and A. M. di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
16. Hoofnagle, J. H., E. Doo, T. J. Liang, R. Fleischer, and A. S. Lok. 2007. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45:1056-1075.
17. Kenney, J. M., C. H. von Bonsdorff, M. Nassal, and S. D. Fuller. 1995. Evolutionary conservation in the hepatitis B virus core structure: comparison of human and duck cores. Structure 3:1009-1019.
18. Kensler, T. W., et al. 2004. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127:S310-S318.
19. Kostenich, G. A., I. N. Zhuravkin, and E. A. Zhavrid. 1994. Experimental grounds for using chlorin e6 in the photodynamic therapy of malignant tumors. J. Photochem. Photobiol. B 22:211-217.
20. Krebs, F. C., S. R. Miller, D. Malamud, M. K. Howett, and B. Wigdahl. 1999. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 43:157-173.
21. Lenhoff, R. J., and J. Summers. 1994. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J. Virol. 68:4565-4571.
22. Lin, L., and J. Hu. 2008. Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds. J. Virol. 82:2305-2312. (Pubitemid 351293530)
23. Lok, A. S. 2009. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet? J. Hepatol. 51:416-418.
24. Mekler, L. B., A. F. Bychovsky, and B. L. Krikun. 1969. Electron microscope study of the viricidal properties of sodium magnesium-chlorophyllin. Nature 222:574-575.
25. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. (Pubitemid 14203433)
26. Moss, B. 2006. Poxvirus entry and membrane fusion. Virology 344:48-54.
27. Rando, R. F., et al. 2006. Critical design features of phenyl carboxylate-containing polymer microbicides. Antimicrob. Agents Chemother. 50:3081-3089.
28. Schormann, W., A. Kraft, D. Ponsel, and V. Bruss. 2006. Hepatitis B virus particle formation in the absence of pregenomic RNA and reverse transcriptase. J. Virol. 80:4187-4190.
29. Seeger, C., and W. S. Mason. 2000. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64:51-68.
30. Seitz, S., S. Urban, C. Antoni, and B. Bottcher. 2007. Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J. 26:4160-4167. (Pubitemid 47462100)
31. Wolf, M. C., et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U. S. A. 107:3157-3162.
32. Zhou, T., et al. 2006. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res.72:116-124.